|
gptkbp:instanceOf
|
gptkb:drug
combination drug
|
|
gptkbp:activeIngredient
|
gptkb:levodopa
gptkb:entacapone
carbidopa
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2003
|
|
gptkbp:ATCCode
|
gptkb:N04BA03
|
|
gptkbp:chemicalClass
|
dopaminergic agent
COMT inhibitor
DOPA decarboxylase inhibitor
|
|
gptkbp:color
|
brownish-orange (tablet)
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
narrow-angle glaucoma
concurrent use with non-selective MAO inhibitors
history of neuroleptic malignant syndrome
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugClass
|
antiparkinsonian agent
|
|
gptkbp:eliminationHalfLife
|
0.4-0.7 hours (entacapone)
0.7-1.4 hours (carbidopa)
1-2 hours (levodopa)
|
|
gptkbp:form
|
film-coated tablet
100/25/200 mg
125/31.25/200 mg
150/37.5/200 mg
200/50/200 mg
50/12.5/200 mg
75/18.75/200 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Stalevo
|
|
gptkbp:indication
|
treatment of Parkinson's disease with end-of-dose motor fluctuations
|
|
gptkbp:interactsWith
|
gptkb:tricyclic_antidepressants
gptkb:MAO_inhibitors
iron salts
antihypertensive drugs
dopamine antagonists
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Orion_Corporation
|
|
gptkbp:marketedAs
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
hallucination
insomnia
dyskinesia
|
|
gptkbp:storage
|
store below 30°C
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
|
|
gptkbp:bfsParent
|
gptkb:Orion_Corporation
|
|
gptkbp:bfsLayer
|
6
|